Nantahala Capital Management’s Acer Therapeutics Inc ACER Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q4 | – | Sell |
-918,349
| Closed | -$748K | – | 146 |
|
|
2023
Q3 | $748K | Sell |
918,349
-218,067
| -19% | -$179K | 0.06% | 108 |
|
|
2023
Q2 | $1.05M | Sell |
1,136,416
-66,710
| -6% | -$59.1K | 0.1% | 90 |
|
|
2023
Q1 | $913K | Sell |
1,203,126
-23,065
| -2% | -$45.5K | 0.07% | 97 |
|
|
2022
Q4 | $3.08M | Buy |
1,226,191
+529,653
| +76% | +$909K | 0.2% | 66 |
|
|
2022
Q3 | $968K | Sell |
696,538
-44,472
| -6% | -$64.4K | 0.06% | 90 |
|
|
2022
Q2 | $934K | Sell |
741,010
-36,810
| -5% | -$77.1K | 0.05% | 97 |
|
|
2022
Q1 | $2.26M | Sell |
777,820
-123,470
| -14% | -$298K | 0.1% | 83 |
|
|
2021
Q4 | $2.06M | Sell |
901,290
-12,907
| -1% | -$30K | 0.07% | 106 |
|
|
2021
Q3 | $2.34M | Sell |
914,197
-20,558
| -2% | -$52.2K | 0.07% | 101 |
|
|
2021
Q2 | $2.67M | Hold |
934,755
| – | – | 0.08% | 105 |
|
|
2021
Q1 | $2.91M | Sell |
934,755
-55,000
| -6% | -$187K | 0.09% | 93 |
|
|
2020
Q4 | $2.59M | Sell |
989,755
-900
| -0.1% | -$2.42K | 0.08% | 97 |
|
|
2020
Q3 | $2.85M | Hold |
990,655
| – | – | 0.09% | 94 |
|
|
2020
Q2 | $3.4M | Hold |
990,655
| – | – | 0.1% | 92 |
|
|
2020
Q1 | $1.97M | Hold |
990,655
| – | – | 0.07% | 93 |
|
|
2019
Q4 | $3.97M | Hold |
990,655
| – | – | 0.12% | 71 |
|
|
2019
Q3 | $3.16M | Hold |
990,655
| – | – | 0.12% | 81 |
|
|
2019
Q2 | $3.86M | Buy |
990,655
+106,200
| +12% | +$2.02M | 0.12% | 79 |
|
|
2019
Q1 | $21.5M | Sell |
884,455
-19,000
| -2% | -$448K | 0.67% | 34 |
|
|
2018
Q4 | $18.2M | Buy |
903,455
+212,067
| +31% | +$4.88M | 0.56% | 44 |
|
|
2018
Q3 | $21.3M | Buy |
691,388
+441,136
| +176% | +$11.8M | 0.57% | 42 |
|
|
2018
Q2 | $5.41M | Hold |
250,252
| – | – | 0.22% | 64 |
|
|
2018
Q1 | $4.82M | Buy |
+250,252
| New | +$4.59M | 0.22% | 60 |
|
Other funds holding ACER
Nantahala Capital Management's ACER Position: Q4 2023 in Review
Nantahala Capital Management sold out of Acer Therapeutics Inc (ACER) in Q4 2023, closing a stake of 918,349 shares — an estimated $748K sold.
Nantahala Capital Management first reported a position in ACER in Q1 2018 and held it in 23 quarters. The position peaked at $21.5M in Q1 2019. 2 funds tracked by Wall St. Rank hold ACER as of Q4 2023.
- Nantahala Capital Management reported no remaining Acer Therapeutics Inc position as of Q4 2023 after selling out during the quarter.
- Nantahala Capital Management sold 918,349 Acer Therapeutics Inc shares in Q4 2023, an estimated $748K.
- Nantahala Capital Management first reported a position in Acer Therapeutics Inc in Q1 2018 and held it in 23 quarters.
- Nantahala Capital Management's Acer Therapeutics Inc position peaked at $21.5M in Q1 2019.
- 2 funds tracked by Wall St. Rank held Acer Therapeutics Inc as of Q4 2023.
Based on Nantahala Capital Management's 13F filing for Q4 2023, filed 14 Feb 2024.